Cargando…
Assessment of the Efficacy of Lowering LDL Cholesterol with Rosuvastatin 10 mg in Four Korean Statin Benefit Groups as per ACC/AHA Guidelines (NewStaR4G)
The American College of Cardiology and American Heart Association (ACC/AHA) guidelines identified four statin benefit groups on the basis of atherosclerotic cardiovascular disease risk reduction and proposed statin therapy by evidence-based intensity. Although these guidelines used randomized contro...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7230727/ https://www.ncbi.nlm.nih.gov/pubmed/32230818 http://dx.doi.org/10.3390/jcm9040916 |
_version_ | 1783535023074312192 |
---|---|
author | Kim, Kyung-Jin Yoon, Junghan Won, Kyung Heon Lim, Sang-Wook Chae, In-Ho Lee, Sung Yun Kim, Sang-Wook Kim, Hyo-Soo |
author_facet | Kim, Kyung-Jin Yoon, Junghan Won, Kyung Heon Lim, Sang-Wook Chae, In-Ho Lee, Sung Yun Kim, Sang-Wook Kim, Hyo-Soo |
author_sort | Kim, Kyung-Jin |
collection | PubMed |
description | The American College of Cardiology and American Heart Association (ACC/AHA) guidelines identified four statin benefit groups on the basis of atherosclerotic cardiovascular disease risk reduction and proposed statin therapy by evidence-based intensity. Although these guidelines used randomized controlled trials with hard outcomes as exclusive evidence for its recommendations, a limited number of studies conducted in Asian countries makes its application of treatment strategy, intensity, and statin doses uncertain in these population. This prospective, multicenter study aimed to evaluate the efficacy of rosuvastatin 10 mg in the four statin benefit groups requiring high- or moderate-intensity statin therapy according to the ACC/AHA guidelines in the Korean population. The primary endpoint was percentage reduction in low-density lipoprotein (LDL) cholesterol. Secondary endpoints were percentage reduction in other lipids and achievement of ≥50% reduction in LDL cholesterol. Rosuvastatin 10 mg lowered LDL cholesterol by 61.4 mg/dL, a 44.9% decrease from baseline after eight weeks. Reduction of LDL cholesterol ≥50% was achieved in 46.3% of patients. Rosuvastatin 10 mg was generally well tolerated. In the Korean population, rosuvastatin 10 mg was favorable and tolerant in lowering LDL cholesterol in the four statin benefit groups requiring high- or moderate-intensity statin therapy according to the ACC/AHA guidelines. |
format | Online Article Text |
id | pubmed-7230727 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-72307272020-05-22 Assessment of the Efficacy of Lowering LDL Cholesterol with Rosuvastatin 10 mg in Four Korean Statin Benefit Groups as per ACC/AHA Guidelines (NewStaR4G) Kim, Kyung-Jin Yoon, Junghan Won, Kyung Heon Lim, Sang-Wook Chae, In-Ho Lee, Sung Yun Kim, Sang-Wook Kim, Hyo-Soo J Clin Med Article The American College of Cardiology and American Heart Association (ACC/AHA) guidelines identified four statin benefit groups on the basis of atherosclerotic cardiovascular disease risk reduction and proposed statin therapy by evidence-based intensity. Although these guidelines used randomized controlled trials with hard outcomes as exclusive evidence for its recommendations, a limited number of studies conducted in Asian countries makes its application of treatment strategy, intensity, and statin doses uncertain in these population. This prospective, multicenter study aimed to evaluate the efficacy of rosuvastatin 10 mg in the four statin benefit groups requiring high- or moderate-intensity statin therapy according to the ACC/AHA guidelines in the Korean population. The primary endpoint was percentage reduction in low-density lipoprotein (LDL) cholesterol. Secondary endpoints were percentage reduction in other lipids and achievement of ≥50% reduction in LDL cholesterol. Rosuvastatin 10 mg lowered LDL cholesterol by 61.4 mg/dL, a 44.9% decrease from baseline after eight weeks. Reduction of LDL cholesterol ≥50% was achieved in 46.3% of patients. Rosuvastatin 10 mg was generally well tolerated. In the Korean population, rosuvastatin 10 mg was favorable and tolerant in lowering LDL cholesterol in the four statin benefit groups requiring high- or moderate-intensity statin therapy according to the ACC/AHA guidelines. MDPI 2020-03-27 /pmc/articles/PMC7230727/ /pubmed/32230818 http://dx.doi.org/10.3390/jcm9040916 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Kim, Kyung-Jin Yoon, Junghan Won, Kyung Heon Lim, Sang-Wook Chae, In-Ho Lee, Sung Yun Kim, Sang-Wook Kim, Hyo-Soo Assessment of the Efficacy of Lowering LDL Cholesterol with Rosuvastatin 10 mg in Four Korean Statin Benefit Groups as per ACC/AHA Guidelines (NewStaR4G) |
title | Assessment of the Efficacy of Lowering LDL Cholesterol with Rosuvastatin 10 mg in Four Korean Statin Benefit Groups as per ACC/AHA Guidelines (NewStaR4G) |
title_full | Assessment of the Efficacy of Lowering LDL Cholesterol with Rosuvastatin 10 mg in Four Korean Statin Benefit Groups as per ACC/AHA Guidelines (NewStaR4G) |
title_fullStr | Assessment of the Efficacy of Lowering LDL Cholesterol with Rosuvastatin 10 mg in Four Korean Statin Benefit Groups as per ACC/AHA Guidelines (NewStaR4G) |
title_full_unstemmed | Assessment of the Efficacy of Lowering LDL Cholesterol with Rosuvastatin 10 mg in Four Korean Statin Benefit Groups as per ACC/AHA Guidelines (NewStaR4G) |
title_short | Assessment of the Efficacy of Lowering LDL Cholesterol with Rosuvastatin 10 mg in Four Korean Statin Benefit Groups as per ACC/AHA Guidelines (NewStaR4G) |
title_sort | assessment of the efficacy of lowering ldl cholesterol with rosuvastatin 10 mg in four korean statin benefit groups as per acc/aha guidelines (newstar4g) |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7230727/ https://www.ncbi.nlm.nih.gov/pubmed/32230818 http://dx.doi.org/10.3390/jcm9040916 |
work_keys_str_mv | AT kimkyungjin assessmentoftheefficacyofloweringldlcholesterolwithrosuvastatin10mginfourkoreanstatinbenefitgroupsasperaccahaguidelinesnewstar4g AT yoonjunghan assessmentoftheefficacyofloweringldlcholesterolwithrosuvastatin10mginfourkoreanstatinbenefitgroupsasperaccahaguidelinesnewstar4g AT wonkyungheon assessmentoftheefficacyofloweringldlcholesterolwithrosuvastatin10mginfourkoreanstatinbenefitgroupsasperaccahaguidelinesnewstar4g AT limsangwook assessmentoftheefficacyofloweringldlcholesterolwithrosuvastatin10mginfourkoreanstatinbenefitgroupsasperaccahaguidelinesnewstar4g AT chaeinho assessmentoftheefficacyofloweringldlcholesterolwithrosuvastatin10mginfourkoreanstatinbenefitgroupsasperaccahaguidelinesnewstar4g AT leesungyun assessmentoftheefficacyofloweringldlcholesterolwithrosuvastatin10mginfourkoreanstatinbenefitgroupsasperaccahaguidelinesnewstar4g AT kimsangwook assessmentoftheefficacyofloweringldlcholesterolwithrosuvastatin10mginfourkoreanstatinbenefitgroupsasperaccahaguidelinesnewstar4g AT kimhyosoo assessmentoftheefficacyofloweringldlcholesterolwithrosuvastatin10mginfourkoreanstatinbenefitgroupsasperaccahaguidelinesnewstar4g |